List of Excipients in Branded Drug DEPO-SUBQ PROVERA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	DEPO-SUBQ PROVERA	medroxyprogesterone acetate	0009-4709	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	DEPO-SUBQ PROVERA	medroxyprogesterone acetate	0009-4709	METHIONINE
Pharmacia & Upjohn Company LLC	DEPO-SUBQ PROVERA	medroxyprogesterone acetate	0009-4709	METHYLPARABEN
Pharmacia & Upjohn Company LLC	DEPO-SUBQ PROVERA	medroxyprogesterone acetate	0009-4709	POLYETHYLENE GLYCOL
Pharmacia & Upjohn Company LLC	DEPO-SUBQ PROVERA	medroxyprogesterone acetate	0009-4709	POLYSORBATE 80

DEPO-SUBQ PROVERA Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

DEPO-SUBQ PROVERA 104 is a subcutaneous depot formulation of medroxyprogesterone acetate, or DMPA, supplied as 104 mg in 0.65 mL. Its commercial value rests on a mature injectable suspension platform, a prefilled delivery system, and the ability to support self-administration. The main excipient opportunity is not a simple reformulation of DMPA. It is the development of a more robust, preservative-free, low-viscosity, device-compatible suspension with longer shelf life, easier injection, and broader global distribution potential.

What is DEPO-SUBQ PROVERA and how does its formulation work?

DEPO-SUBQ PROVERA is a progestin-only contraceptive injection administered subcutaneously once every three months. The active ingredient is medroxyprogesterone acetate, a poorly water-soluble steroid formulated as a crystalline suspension rather than as a solution.

The U.S. product contains 104 mg of medroxyprogesterone acetate in 0.65 mL. The labeled inactive ingredients include polyethylene glycol 3350, polysorbate 80, sodium chloride, and methylparaben. Hydrochloric acid or sodium hydroxide may be used for pH adjustment. The product is supplied in a prefilled glass syringe intended for subcutaneous injection.[1]

Attribute	DEPO-SUBQ PROVERA 104
Active ingredient	Medroxyprogesterone acetate
Dose	104 mg
Volume	0.65 mL
Route	Subcutaneous
Dosing interval	Approximately 12 to 13 weeks
Dosage form	Injectable suspension
Primary excipient functions	Wetting, viscosity control, isotonicity, preservation
Delivery system	Prefilled syringe
Originator	Pfizer
U.S. regulatory pathway	505(b)(2)/NDA product pathway
Initial U.S. approval	2004

The formulation must keep the drug particles uniformly dispersed during storage, permit accurate withdrawal or delivery of the dose, and prevent excessive sedimentation or caking. The product also must pass through a subcutaneous needle without unacceptable injection force.

What excipients are used in DEPO-SUBQ PROVERA?

The core excipient system has four functional components.

Polyethylene glycol 3350

Polyethylene glycol 3350 acts primarily as a vehicle and viscosity-modifying excipient. It can influence particle sedimentation, suspension rheology, and injection behavior. Its concentration must be balanced carefully. Higher viscosity may improve physical stability but can increase injection force and impair delivery through a fine needle.

PEG 3350 also affects the interfacial environment around hydrophobic steroid particles. A reformulation strategy would need to assess molecular-weight distribution, peroxide content, viscosity, extractables, and compatibility with container-closure components.

Polysorbate 80

Polysorbate 80 is a nonionic surfactant used to improve wetting and dispersion of medroxyprogesterone acetate particles. It can reduce agglomeration and support redispersion after storage.

Its main development risks are oxidation, hydrolysis, peroxide formation, and interaction with packaging materials. These risks can affect particle growth, potency, impurities, and product appearance. A lower-peroxide polysorbate grade or an alternative surfactant may create a defensible formulation improvement if it produces measurable stability or tolerability gains.

Sodium chloride

Sodium chloride contributes to isotonicity and helps align the formulation with subcutaneous tissue tolerability requirements. Changes in ionic strength can alter particle interactions, sedimentation, viscosity, and preservative performance.

A replacement with another tonicity agent could reduce precipitation or improve syringeability, but it would require a complete assessment of osmolality, local tolerability, and long-term suspension behavior.

Methylparaben

Methylparaben provides antimicrobial preservation. It is commercially useful in multidose products but creates potential limitations for preservative-sensitive patients, pediatric applications, and markets that favor preservative-free presentations.

A preservative-free, single-dose presentation is one of the clearest product-extension opportunities. That strategy would shift microbiological control from chemical preservation to aseptic manufacturing and container-closure integrity.

What excipient strategy could improve DEPO-SUBQ PROVERA?

The most commercially relevant excipient strategies are focused on injection performance, stability, tolerability, and manufacturing robustness.

Strategy	Technical objective	Commercial benefit	Main regulatory risk
Low-peroxide surfactant system	Reduce oxidation and particle instability	Longer shelf life and lower impurity burden	New excipient characterization
Preservative-free formulation	Eliminate methylparaben	Broader patient acceptance and single-dose positioning	Aseptic-process and container-closure burden
Alternative wetting agent	Improve redispersion and reduce agglomeration	Better dose uniformity	Local tolerability and comparability
Lower-viscosity vehicle	Reduce injection force	Smaller needle and improved self-injection	Sedimentation and dose-delivery risk
Controlled particle-size distribution	Improve suspension uniformity	More consistent dose delivery	Process-control and bioequivalence requirements
Novel rheology modifier	Control settling without excessive viscosity	Better shelf stability and device compatibility	New toxicology and manufacturability work
Antioxidant strategy	Protect surfactant and steroid from degradation	Improved stability	Compatibility and impurity qualification
Siliconization reduction	Reduce particle or protein-like interfaces, where relevant	Lower visible and subvisible particulate risk	Syringe glide-force performance

The highest-probability path is incremental optimization of the existing excipient platform. A new polymer or complex carrier would increase development cost and could create a new regulatory package without producing a proportional clinical benefit.

What formulations are protected by DEPO-SUBQ PROVERA patents?

The original commercial protection for DEPO-SUBQ PROVERA is likely to be less important than regulatory exclusivity, manufacturing know-how, device integration, and supply-chain qualification because the product was approved in 2004.

For a mature small-molecule suspension, the most relevant intellectual-property categories are:

1. Composition claims covering the drug concentration and excipient ratios.
2. Particle-size and particle-morphology claims.
3. Suspension-stability and redispersion claims.
4. Prefilled-syringe and needle-interface claims.
5. Manufacturing claims covering micronization, sterilization, mixing, filling, and hold times.
6. Method-of-use claims covering subcutaneous administration or contraceptive dosing intervals.
7. Combination claims covering the drug suspension and delivery device.

The strongest new patent opportunity would generally come from a technically specific formulation or device limitation, such as a defined particle-size distribution combined with a low-peroxide surfactant and a specified injection-force profile. Broad claims to medroxyprogesterone acetate suspension alone are likely to face prior-art and obviousness challenges.

How strong is the patent estate for DEPO-SUBQ PROVERA?

The legacy formulation estate is likely weaker than a recent complex injectable product estate because of the product’s age and the extensive prior art surrounding DMPA suspensions. Commercial exclusivity is more likely to depend on:

• Manufacturing reproducibility.
• FDA-approved product status.
• Device and fill-finish qualification.
• Supplier relationships for sterile excipients.
• Clinical and real-world experience.
• Brand recognition in contraceptive markets.
• Patentable improvements to self-injection and product presentation.

A follow-on manufacturer should not assume that a different excipient concentration eliminates all infringement risk. It would need to review Orange Book listings, issued patents, pending continuations, terminal disclaimers, and litigation history before selecting a development path.

What is the Orange Book status of DEPO-SUBQ PROVERA?

DEPO-SUBQ PROVERA is associated with Pfizer’s U.S. new drug application for medroxyprogesterone acetate injectable suspension. The FDA Orange Book is the controlling source for currently listed patents, use codes, and regulatory exclusivity. Orange Book status can change through patent-listing updates, delistings, expiration, and litigation outcomes.[2]

For commercial planning, the relevant distinction is between:

• FDA approval of the reference product.
• Listed patents that may support a Paragraph IV challenge.
• Unlisted manufacturing or device patents.
• Trade secrets covering suspension processing and aseptic filling.
• Regulatory data and clinical experience that may not be directly replicable by a generic sponsor.

Because DMPA is a small molecule, biosimilar regulation does not apply. A competing product would proceed through an abbreviated or alternative small-molecule pathway, not the biosimilar pathway used for biological products.

When does DEPO-SUBQ PROVERA lose exclusivity?

The product’s original market exclusivity period has long expired. The remaining commercial barriers are therefore expected to arise from patent status, FDA approval requirements, manufacturing complexity, and market access rather than from new-chemical-entity exclusivity.

A generic or follow-on product would need to address:

• Pharmaceutical equivalence.
• Injectable suspension particle characteristics.
• Sterility and particulate controls.
• Dose uniformity.
• Container-closure integrity.
• Injection-force and device performance.
• Pharmacokinetic comparability.
• Labeling and clinical-use differences.

A Paragraph IV certification could be relevant if unexpired Orange Book patents remain listed. The timing of generic entry would depend on the sponsor’s patent certifications, FDA review, litigation, any 30-month stay, and settlement terms. No general assumption of immediate generic launch is appropriate for a prefilled injectable product.

What generic entry risks exist for DEPO-SUBQ PROVERA?

Generic entry risk is moderate rather than equivalent to the risk for a conventional oral tablet. DMPA itself is well known, but the product has several development barriers.

Formulation barriers

Medroxyprogesterone acetate is hydrophobic and requires controlled particle engineering. A generic sponsor must reproduce clinically relevant suspension behavior without necessarily copying every formulation parameter.

Device barriers

A prefilled syringe introduces requirements for glide force, break-loose force, needle attachment, extractables and leachables, and dose recovery. A product that is pharmaceutically equivalent but difficult to inject may face commercial rejection.

Manufacturing barriers

Sterile suspension manufacture requires control of particle size, microbial contamination, endotoxin, mixing, filling, and sedimentation during process holds. Scale-up can alter particle distribution and redispersion.

Market barriers

Contraceptive providers may prefer established products because dosing errors, administration problems, or missed injections have direct clinical consequences. A lower-priced generic would need reliable supply and strong wholesaler coverage.

Which companies are challenging or competing with DEPO-SUBQ PROVERA?

The competitive field includes several product types rather than a single direct generic category.

Competitor	Active ingredient or technology	Administration	Competitive relevance
Depo-Provera CI	Medroxyprogesterone acetate	Intramuscular injection	Same active ingredient and longer-established route
Sayana Press	Medroxyprogesterone acetate	Subcutaneous injection	Closest global product analogue
Generic DMPA products	Medroxyprogesterone acetate	Usually intramuscular or subcutaneous, depending on product	Price competition
Nexplanon	Etonogestrel	Subdermal implant	Long-acting alternative
Mirena and other LNG-IUDs	Levonorgestrel	Intrauterine device	Long-duration local hormonal contraception
Oral progestins and combined pills	Various	Oral	Lower device complexity but adherence burden
Copper IUDs	Copper	Intrauterine device	Nonhormonal long-acting alternative

Pfizer’s commercial position is strongest where patients or providers value a quarterly injectable and where the subcutaneous route improves access or enables self-administration.

What commercial opportunities exist for DEPO-SUBQ PROVERA excipients?

The most attractive commercial opportunities are formulation and delivery improvements that can be linked to measurable user benefits.

Preservative-free single-dose syringe

A preservative-free presentation could target patients with preservative sensitivity and markets that prefer single-use products. It may also simplify positioning for self-administration. The tradeoff is greater dependence on aseptic processing and container-closure validation.

Self-injection optimization

A lower-viscosity or better-redispersing suspension could support a smaller needle, lower injection force, or a more user-friendly autoinjector. This is commercially relevant because the subcutaneous route is compatible with decentralized administration, including clinics, pharmacies, and home use where permitted.

Extended shelf life

A formulation that reduces surfactant oxidation, particle growth, or caking could support longer expiry and reduce inventory losses. The commercial benefit is strongest in countries with long distribution chains and intermittent cold-chain infrastructure.

Low-resource market presentation

The DMPA-SC platform has been used in public-health settings where self-injection and task shifting can expand contraceptive access. A robust formulation packaged in a compact prefilled system could reduce provider time and improve rural distribution.[3]

Device-compatible reformulation

A manufacturer could pair the suspension with a proprietary syringe, autoinjector, or needle-protection system. Device claims may provide stronger differentiation than broad excipient claims if the formulation is otherwise conventional.

What patent and regulatory strategy should protect a new formulation?

A commercially credible strategy should combine composition, process, and device claims.

Patent claim architecture

Priority claims should cover:

• Drug concentration and excipient ranges.
• Surfactant impurity or peroxide limits.
• Particle-size distribution.
• Redispersion time.
• Sedimentation profile.
• Injection-force range.
• Container and needle configuration.
• Manufacturing sequence and hold times.
• Stability performance under accelerated conditions.
• Preservative-free sterile presentation.

The patent should include multiple fallback positions. A claim limited only to exact excipient percentages may be easy to design around. Functional claims should be supported by reproducible analytical methods and stability data.

FDA pathway

A follow-on product would generally require an ANDA if it can demonstrate sameness to the reference product. A materially different formulation, route, device, or clinical profile could require a 505(b)(2) application. The regulatory classification would depend on the extent of formulation and delivery-system differences.[4]

For injectable suspensions, the development program should include:

• Comparative particle-size analysis.
• Drug-release and dissolution testing where relevant.
• Pharmacokinetic comparison.
• Local tolerability assessment.
• Sterility and endotoxin testing.
• Syringe and needle performance.
• Extractables and leachables.
• Stability under shipping and temperature excursions.

How does DEPO-SUBQ PROVERA compare with other long-acting contraceptives?

DEPO-SUBQ PROVERA has lower administration frequency than oral contraception but a shorter duration than implants and intrauterine systems. Its main advantages are reversibility, a non-daily regimen, and a relatively simple injectable presentation. Its principal limitations include repeat visits or training, delayed return to fertility for some users, injection-related concerns, and bone-mineral-density warnings in the U.S. label.[1]

Product class	Typical duration	Main formulation opportunity	Main commercial limitation
DMPA-SC	About 3 months	Excipient and self-injection optimization	Repeat dosing
DMPA-IM	About 3 months	Lower-cost sterile suspension	Provider administration
Implant	Up to several years	Polymer and drug-release control	Insertion and removal
Hormonal IUD	Several years	Polymer reservoir and device design	Intrauterine placement
Oral contraception	Daily	Solubility and adherence technologies	Daily compliance

What is the commercial outlook for excipient suppliers?

Excipient suppliers can create value by supplying qualified, low-impurity materials rather than generic commodity grades. The highest-value offerings include:

• Low-peroxide polysorbate 80.
• Pharmaceutical-grade PEG 3350 with tight molecular-weight control.
• Preservative systems suitable for sterile suspensions.
• Rheology modifiers with injectable toxicology packages.
• Technical support for particle wetting and suspension stability.
• Packaging-compatible excipient grades.
• Stability-indicating analytical methods.

Supplier differentiation depends on regulatory documentation, lot-to-lot consistency, global manufacturing redundancy, and the ability to support customer change-control filings. An excipient change in a mature injectable product can trigger significant comparability work, creating switching costs once a supplier is qualified.

Key Takeaways

• DEPO-SUBQ PROVERA is a 104 mg/0.65 mL subcutaneous suspension of medroxyprogesterone acetate.
• Its core excipients are PEG 3350, polysorbate 80, sodium chloride, and methylparaben.
• The strongest reformulation opportunities are preservative-free delivery, lower injection force, improved redispersion, and longer shelf life.
• DMPA is a small molecule, so biosimilar competition does not apply.
• Generic risk is constrained by sterile suspension manufacturing, particle control, device performance, and regulatory comparability.
• New patents are more likely to be defensible around defined formulation-performance combinations, manufacturing controls, and delivery devices than around DMPA suspension concepts alone.
• The commercial opportunity is strongest in self-injection, low-resource distribution, pharmacy administration, and qualified high-purity excipient supply.
• Current Orange Book listings and patent litigation should be reviewed before making a launch or licensing decision.

FAQs

Is DEPO-SUBQ PROVERA a solution or a suspension?

It is a suspension. Medroxyprogesterone acetate is dispersed as solid particles in an injectable vehicle.

Can methylparaben be removed from DEPO-SUBQ PROVERA?

Yes, a preservative-free version is technically possible, but it would require an aseptic single-dose strategy, container-closure validation, and regulatory comparability work.

Does DEPO-SUBQ PROVERA require biosimilar approval?

No. Medroxyprogesterone acetate is a small molecule. A competing product would generally use an abbreviated or 505(b)(2) small-molecule pathway.

What is the best excipient opportunity for a generic DMPA-SC product?

The most practical opportunity is a low-viscosity, rapidly redispersible suspension that maintains dose uniformity while reducing injection force and supporting a user-friendly prefilled device.

Can a new excipient create patent protection for a DMPA injectable?

Yes, if the excipient produces a non-obvious and reproducible technical effect, such as improved stability, reduced injection force, enhanced redispersion, or reduced impurity formation. Broad claims to routine excipient substitution would face a higher invalidity risk.

References

1. Pfizer. (2024). DEPO-SUBQ PROVERA 104: Prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. World Health Organization. (2022). Self-administered subcutaneous depot medroxyprogesterone acetate for contraception: Guidance and implementation considerations. World Health Organization.

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA Center for Drug Evaluation and Research.